Sugi Predict

Sugi Predict / Compounds / SCHEMBL571701

SCHEMBL571701

SCHEMBL571701

O=[N+]([O-])c1ccc(CO)cc1F

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 1/20 0.58
▸ TDP1 Q9NUW8 1/20 0.58
▸ ALDH1A1 P00352 3/20 0.47
▸ MAPT P10636 1/20 0.47
▸ TTR P02766 1/20 0.43
▸ HIF1A Q16665 2/20 0.43
▸ PTGES O14684 1/20 0.43
▸ VCAM1 P19320 1/20 0.41
▸ CYP4F2 P78329 1/20 0.40
▸ CYP4A11 Q02928 1/20 0.40
▸ LMNA P02545 3/20 0.40
▸ RECQL P46063 1/20 0.40
▸ SNCA P37840 1/20 0.39
▸ TSHR P16473 2/20 0.39
▸ GPR35 Q9HC97 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ CTSK P43235 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16246163 0.86 ATM (0.55) ATMTDP1ALDH1A1MAPTHIF1A
SCHEMBL545367 0.85 ALDH1A1 (0.56) ATMTDP1ALDH1A1MAPTTTR
SCHEMBL29990481 0.85 ALDH1A1 (0.56) ATMTDP1ALDH1A1MAPTTTR
SCHEMBL515466 0.82 MAPT (0.54) ATMTDP1ALDH1A1MAPTTTR
SCHEMBL146624 0.81 TDP1 (0.58) ATMTDP1ALDH1A1MAPTHIF1A
SCHEMBL29490181 0.81 TDP1 (0.58) ATMTDP1ALDH1A1MAPTHIF1A
SCHEMBL76729 0.81 TDP1 (0.58) ATMTDP1ALDH1A1MAPTHIF1A
SCHEMBL31455558 0.81 TDP1 (0.58) ATMTDP1ALDH1A1MAPTHIF1A
SCHEMBL11439528 0.81 TDP1 (0.58) ATMTDP1ALDH1A1MAPTHIF1A
SCHEMBL12208065 0.81 TDP1 (0.58) ATMTDP1ALDH1A1MAPTHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4620951-A1 MEMANTINE UREA DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN PREPARATION OF MEDICAMENT FOR TREATING SOLUBLE EPOXIDE ENZYME-MEDIATED DISEASES Shenyang Pharmaceutical University (CN) 2025-09-24 — — EP disclosed
EP-4598933-A1 PHOSPHORAMIDATE COMPOUNDS AND USES THEREOF Allorion Therapeutics Inc (US) 2025-08-13 — — EP disclosed
CN-119968377-A Phosphoramidate compounds and uses thereof 安锐生物医药公司 2025-05-09 — — CN disclosed
CN-115819328-B Memantine urea derivatives, preparation method thereof and application thereof in preparation of medicines for treating soluble epoxide enzyme mediated diseases 沈阳药科大学 2024-08-27 — — CN disclosed
US-20240261426-A1 CONJUGATES COMPRISING PHOSPHOANTIGENS AND THEIR USE IN THERAPY BYONDIS B.V. (NL) 2024-08-08 — — US disclosed
WO-2024104411-A1 MEMANTINE UREA DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN PREPARATION OF MEDICAMENT FOR TREATING SOLUBLE EPOXIDE ENZYME-MEDIATED DISEASES 沈阳药科大学 2024-05-23 — — WO disclosed
EP-4362982-A1 CONJUGATES COMPRISING PHOSPHOANTIGENS AND THEIR USE IN THERAPY Byondis B.V. (NL) 2024-05-08 — — EP disclosed
WO-2024078392-A1 PHOSPHORAMIDATE COMPOUNDS AND USES THEREOF ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) 2024-04-18 — — WO disclosed
CN-112266328-B Synthetic route and preparation method of 3-fluoro-4-nitrobenzaldehyde 郑州萃智医药科技有限公司 2023-11-03 — — CN disclosed
CN-116947740-A Hydroxamic acid compound containing urea structure, preparation method thereof and application of hydroxamic acid compound in preparation of HDAC and sEH dual inhibitors 沈阳药科大学 2023-10-27 — — CN disclosed
WO-2005058869-A1 AMINOBENZIMIDAZOLES AND BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION TIBOTEC PHARMACEUTICALS LTD. (IE) 2005-06-30 — — WO disclosed
EP-1531813-A1 USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY Applied Research Systems ARS Holding N.V. (AN) 2005-05-25 — — EP disclosed
EP-1442039-A1 PYRIMIDO (4,5-B) INDOLE DERIVATIVES Bayer HealthCare AG (DE) 2004-08-04 — — EP disclosed
WO-2004058764-A1 4-PHENYL-PYRIMIDO [4,5-B] INDOLE DERIVATIVES BAYER HEALTHCARE AG (DE) 2004-07-15 — — WO disclosed
EP-1434579-A1 IMIDAZOLE DERIVATIVES AS ANTIINFLAMMATORY AGENTS Tularik Inc. (US) 2004-07-07 — — EP disclosed
WO-2004006916-A1 USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) 2004-01-22 — — WO disclosed
WO-2004007491-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2004-01-22 — — WO disclosed
US-20030144286-A1 Benzimidazole derivatives TULARIK, INC 2003-07-31 — — US disclosed
WO-2003037898-A1 PYRIMIDO [4,5-B] INDOLE DERIVATIVES BAYER HEALTHCARE AG (DE) 2003-05-08 — — WO disclosed
WO-2003030902-A1 IMIDAZOLE DERIVATES AS ANTI-INFLAMMATORY AGENTS TULARIK INC. (US) 2003-04-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240261426-A1 CONJUGATES COMPRISING PHOSPHOANTIGENS AND THEIR USE IN THERAPY CD47, PTMS, PAG1 ATM 731/4885TDP1 2767/4885ALDH1A1 4466/4885
US-20030144286-A1 Benzimidazole derivatives NFATC1, STAT1, IRF3 ATM 587/4885TDP1 3564/4885ALDH1A1 1869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.